2022 American Transplant Congress
Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox
*Purpose: Predicting kidney transplant patient mortality has been hampered by registry-based studies and low level phenotyped cohorts without specific design towards mortality prediction. This represents…2022 American Transplant Congress
Prospective Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) in Monitoring Response to Anti-Rejection Treatment in Kidney Transplant Recipients with Indication Biopsy
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a marker of allograft injury in kidney transplant recipients (KTR). Little is known about the possible use of dd-cfDNA…2022 American Transplant Congress
Post-Xenotransplant Antibody Specificities Against Swine, Monkey and Human Leukocyte Antigens in Highly Sensitized Nonhuman Primate Model
Surgery, Duke Transplant Center, Durham, NC
*Purpose: Xenotransplantation has been proposed as a bridge to transplant for allosensitized patients. However, the potential of xenotransplantation to broaden HLA allosensitization due to MHC…2022 American Transplant Congress
Preliminary Data of the Safety and Immunogenicity Protocol of Vaccination for SARS-CoV 2 in Solid Organ Transplant Patients in Argentina
*Purpose: To evaluate the safety and generation rate of Ab anti spike rate in SOT patients at 28 and 90 days after completing the Covid…2022 American Transplant Congress
Kidney Transplant Recipients Not Reaching the Expected Post-Transplant Creatinine Range Most Likely Show Calcineurin-Inhibitor Nephrotoxicity Upon Histology
1University Hospital Zürich, Zürich, Switzerland, 2University Hospital Zurich, Zürich, Switzerland
*Purpose: Very recently, our own data suggested that approximately 25% of deceased-donor kidney transplant recipients (KTRs) and 10% of living-donor KTRs don’t reach the expected…2022 American Transplant Congress
Use of De Novo mTOR Inhibitors in Highly Sensitized Kidney Transplant Recipients
*Purpose: mTOR inhibitors (mTORi) allow calcineurin-inhibitor reduction without loss of efficacy and may improve allograft-transplant outcomes. However, the safety of this protocol in high-immunological risk…2022 American Transplant Congress
No Difference in Graft Survival Among Low Socioeconomic Kidney Allograft Recipients
*Purpose: Low socioeconomic status remains a barrier in access and equity in kidney transplantation with limited data assessing post-transplant outcomes. Alternative options to transplantation include…2022 American Transplant Congress
A Novel Mismatch That Modulates the Innate Alloresponse Risk Stratifies Renal Transplant Patients
Thomas E. Starzl Transplantation Institute, UPMC, Pittsburgh, PA
*Purpose: Donor polymorphism in the gene encoding signal regulatory protein alpha (SIRPα) is a key modulator of the recipient’s innate alloresponse. Here, we investigated the…2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…2022 American Transplant Congress
Impact of Target Tacrolimus Levels on BK Polyomavirus DNAemia and Allograft Rejection Among Pediatric Kidney Transplant Recipients
*Purpose: BK Polyomavirus (BK) DNAemia is a serious and common infectious complication after kidney transplant (KT). We evaluated the impact of targeting lower tacrolimus levels…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 531
- Next Page »